SCHEMBL29533339

SCHEMBL29533339

O=Cc1cccc(S(=O)(=O)N2CCOCC2)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
KDM4E B2RXH2 1/20 0.59
HTT P42858 1/20 0.59
TSHR P16473 2/20 0.57
RECQL P46063 1/20 0.57
HPGD P15428 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
POLB P06746 3/20 0.53
GAA P10253 1/20 0.51
PKM P14618 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3343124 1.00 ALDH1A1 (0.59) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL15652183 0.86 ALDH1A1 (0.65) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL1003525 0.84 ALDH1A1 (0.63) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL15651824 0.82 PKM (0.56) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL15650298 0.82 POLB (0.61) HTTTSHRLMNASMN1; SMN2POLB
SCHEMBL16888223 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL20568836 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL847277 0.81 POLB (0.69) ALDH1A1KDM4EHTTTSHRMEN1
SCHEMBL29257268 0.79 ALDH1A1 (0.45) ALDH1A1HTTTSHRHPGDMEN1
SCHEMBL1196165 0.78 TSHR (0.63) ALDH1A1KDM4EHTTTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228624-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed